Company / Operating Income
Terns Pharmaceuticals, Inc. Operating Income History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$101.9M
FY2024
5-year range
-$102.6M / -$37.0M
FY2020-FY2024
Trend
+0.7%
vs FY2023
Sector context
#95 of 202
Health Care
What the data says
At -$102M, Terns Pharmaceuticals, Inc.'s operating income ranks #95 of 202 in the Health Care sector. Operating Income returned to growth in FY2024 after 3 years of decline, reaching -$102M.
Based on SEC 10-K filings.
-$102M in FY2024.
Declined from -$62M to -$102M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#95 of 202 in Health CareTop 47% of 202This company -$101.9M Sector average $70.7M
▼
-244.1% below sector average
Key checks
Key Insights
- In FY2024, operating income increased 0.7% year-over-year.
- Ranks #95 out of 202 companies in the Health Care sector.
- Peak operating income was recorded in FY2020.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 7.86 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$101.9M | +0.7% |
| FY2023 | -$102.6M | -65.3% |
| FY2022 | -$62.0M | -24.4% |
| FY2021 | -$49.9M | -34.7% |
| FY2020 | -$37.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026